11 results about "Fusion peptide" patented technology

Provided herein is a hypervesiculating Escherichia coli Nissle (ΔECHy) bacterium engineered to produce outer membrane vesicles (OMVs), said OMVs packaging a fusion peptide including cytolysin A (ClyA) and hyaluronidase (Hy). Also provided are methods of remodeling a tumor, methods of treating cancer, and pharmaceutical compositions including the engineered ΔECHy bacterium.

The present disclosure relates to an implantable vascular graft material, including: a substrate including a graft material, the substrate defining a top surface and a bottom surface; and one or more bispecific binding partners having a luminal binding domain bound to the top surface and one or more cellular binding domains. In embodiments, the disclosure includes an implantable vascular graft including: a tubular base layer including a graft material, the tubular base layer defining a luminal surface and an abluminal surface; and a fusion peptide having a heparin binding domain bound to the luminal surface and one or more monocyte binding domains. In embodiments, the present disclosure provides one or more implantable vascular grafts such as A-TEVs, methods of making vascular grafts, methods of use, and the like.

The invention discloses a screening and fermentation preparation method of high-yield antibacterial peptide probiotics, and relates to the technical field of microbial fermentation and animal nutrition, the method comprises three core steps of intestinal colonization-oriented multi-phenotype collaborative screening, self-assembled antibacterial peptide engineering bacterium construction, and in-situ nanocrystallization fermentation preparation. The preparation method comprises the following steps: firstly, screening out a probiotic host with gastrointestinal tolerance, colonization capability and self-assembly precursor peptide secretion potential, then constructing a fusion gene engineering bacterium containing an intestinal environment induced promoter, and finally, performing staged fermentation to realize fusion peptide in-situ self-assembly and spray drying to obtain a finished product, and the finished product contains colonization type recombinant viable bacteria and antibacterial peptide nanoparticles. The method can realize targeted colonization and long-acting bacteriostasis of intestinal tracts, has application stability and efficacy persistence, and is suitable for production of feed antibacterial peptide preparations.

The present invention relates to a fusion peptide, a salt thereof, or a solvate thereof, the fusion peptide containing, from the amino terminus toward the carboxy terminus, a tag peptide and any peptide among (A1)-(A3). (A1) A peptide that comprises the amino acid sequence represented by SEQ ID NO: 1; (A2) a peptide that comprises an amino acid sequence obtained by deleting, substituting, or adding 1-4 amino acids in the amino acid sequence represented by SEQ ID NO: 1 and that has a pore density increasing effect; and (A3) a peptide that comprises an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 1 and that has a pore density increasing effect.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

This invention discloses a recombinant BCG vaccine expressing a multi-epitope fusion peptide of foot-and-mouth disease virus (FMD) types O and A and its application, belonging to the fields of biotechnology and veterinary vaccines. The amino acid sequence of the multi-epitope fusion peptide is shown in SEQ ID NO:1, containing dominant immune T-cell and B-cell antigenic epitopes from multiple circulating FMD virus types O and A, and fused with a mycobacterial signal peptide at the N-terminus. This invention successfully constructed the recombinant strain rBCG-MIPGA by codon optimization of the fusion gene, cloning it into the pMV306 vector, and electroporating it into BCG. This recombinant BCG can simultaneously stimulate high-titer specific antibodies and significant T-cell immune responses against FMD virus types O and A, exhibiting durable and broad-spectrum protective potential, and has significant application value in the preparation of safe, efficient, and broad-spectrum FMD vaccines.

This invention belongs to the field of biomedical technology, specifically relating to a pharmaceutical composition for treating allergic conjunctivitis in children, its preparation method, and its uses. The pharmaceutical composition of this invention comprises hsa-miR-19b mimic and an immune peptide, wherein the immune peptide is a fusion peptide NGF-FGF, a combination of nerve growth factor (NGF) and fibroblast growth factor (FGF). In vitro and in vivo experiments have confirmed that hsa-miR-19b mimic and the fusion peptide NGF-FGF can alleviate the course of allergic conjunctivitis in children and reduce allergic symptoms by inhibiting the expression of inflammatory factors and reducing inflammatory responses.

Provided is a cell having improved tissue compatibility with a transplantation subject. Specifically, by knocking a polynucleotide encoding a single-chain fusion peptide that mimics HLA-G and / or HLA-E that has an inhibitory effect on the activity (cell damage) of NK cells and macrophages into a region encoding the alpha chain of an HLA class I molecule, it is possible to inhibit the expression of the alpha chain of the HLA class I molecule while expressing the single-chain fusion peptide.

The invention discloses a multi-epitope peptide of Ebola virus, a vaccine as well as a preparation method and application of the multi-epitope peptide and the vaccine, and belongs to the technical field of biological medicines. The multi-epitope peptide is derived from surface glycoprotein (Glycoprotein, GP) of Zaire type Ebola virus and Sudan type Ebola virus, and the epitope peptide is conserved in the two types of Ebola viruses. In addition, the multi-epitope peptide is both a T cell epitope and a B cell epitope. An epitope peptide and a nano delivery carrier are connected through a linker to prepare a vaccine, the vaccine comprises the multi-epitope peptide or a combination thereof, a free KFE8 self-assembly peptide and a PADRE-KFE8 fusion peptide, and a nano fiber structure is formed through self-assembly of the multi-epitope peptide or the combination thereof, the free KFE8 self-assembly peptide and the PADRE-KFE8 fusion peptide. The preparation method comprises the following steps: dissolving the components in a buffer solution according to a specific molar ratio, and incubating to enable the components to be self-assembled to form nanofibers. The multi-epitope peptide can be used for preparing a vaccine for preventing Ebola virus infection, and the vaccine can induce humoral immunity and cellular immunity at the same time, and has broad-spectrum protection potential for Zaire type and Sudan type Ebola viruses at the same time.

The invention provides an immune T cell preparation and application thereof in tumor treatment, and belongs to the technical field of cell biology. According to the method, human peripheral blood CD8 positive T cells are used as starting cells, and sequence-improved fusion peptide DerB-MA-1 is used for in-vitro induction. Experimental results show that T cells pretreated by DerB-MA-1 show extremely high killing activity under a normal oxygen condition, and the killing activity is remarkably superior to that of other fusion peptides. More importantly, under the hypoxia condition of simulating the tumor microenvironment, the preparation c can still maintain the potent killing rate. Therefore, the invention successfully overcomes the technical bottleneck of function decline of T cells in an anoxic environment, realizes obvious breakthrough of T cell functions, and has important clinical application value in immune cell therapy of solid tumors such as melanoma and the like.

Disclosed herein are compositions and methods for controlling respiratory syncytial virus (RSV) infection. In certain embodiments, vaccines and pharmaceutical compositions comprise or encode RSV G proteins comprising the mutations or fusion protein arrangements disclosed herein. In certain embodiments, viral particles / virus-like particles, nucleic acids, vectors, or attenuated RSV vaccines are used in the methods reported herein.